TY - JOUR
T1 - Deletion of soluble epoxide hydrolase attenuates cardiac hypertrophy via down-regulation of cardiac fibroblasts-derived fibroblast growth factor-2
AU - Zhang, Huanji
AU - Wang, Tong
AU - Zhang, Kun
AU - Liu, Yu
AU - Huang, Feifei
AU - Zhu, Xinhong
AU - Liu, Yang
AU - Wang, Mong-Heng
AU - Tang, Wanchun
AU - Wang, Jingfeng
AU - Huang, Hui
PY - 2014/5
Y1 - 2014/5
N2 - Objective: Inhibition of soluble epoxide hydrolase (Ephx2) has been shown to play a protective role in cardiac hypertrophy, but the mechanism is not fully understood. We tested the hypothesis that deletion of soluble epoxide hydrolase attenuates cardiac hypertrophy via down-regulation of cardiac fibroblasts-derived fibroblast growth factor-2. Design: Prospective, controlled, and randomized animal study. Setting: University laboratory. Subjects: Male wild-type C57BL/6 mice and Ephx2 (-/-) mice. Interventions: Male wild-type or Ephx2 (-/-) mice were subjected to transverse aorta constriction surgery. Measurements and Main Results: Four weeks after transverse aorta constriction, Ephx2 (-/-) mice did not develop significant cardiac hypertrophy as that of wild-type mice, indicated by no changes in the ratio of heart weight/body weight and ventricular wall thickness after transverse aorta constriction. Cardiac fibroblast growth factor-2 increased in wild-type-transverse aorta constriction group but this did not change in Ephx2 (-/-)-transverse aorta constriction group, and the serum level of fibroblast growth factor-2 did not change in both groups. In vitro, cardiac fibroblasts were stimulated by angiotensin II to analyze the expression of fibroblast growth factor-2. The effect of increased fibroblast growth factor-2 from cardiac fibroblasts induced by angiotensin II was attenuated by soluble epoxide hydrolase deletion. ERK1/2, p38, and AKT kinase were involved in fibroblast growth factor-2 expression regulated by angiotensin II, and soluble epoxide hydrolase deletion lowered the phosphorylation of ERK1/2 not p38 or AKT to mediate fibroblast growth factor-2 expression. In addition, soluble epoxide hydrolase deletion did not attenuate cardiomyocytes hypertrophy induced by exogenous fibroblast growth factor-2. Conclusions: Our present data demonstrated that deletion of soluble epoxide hydrolase prevented cardiac hypertrophy not only directly to cardiomyocytes but also to cardiac fibroblasts by reducing expression of fibroblast growth factor-2.
AB - Objective: Inhibition of soluble epoxide hydrolase (Ephx2) has been shown to play a protective role in cardiac hypertrophy, but the mechanism is not fully understood. We tested the hypothesis that deletion of soluble epoxide hydrolase attenuates cardiac hypertrophy via down-regulation of cardiac fibroblasts-derived fibroblast growth factor-2. Design: Prospective, controlled, and randomized animal study. Setting: University laboratory. Subjects: Male wild-type C57BL/6 mice and Ephx2 (-/-) mice. Interventions: Male wild-type or Ephx2 (-/-) mice were subjected to transverse aorta constriction surgery. Measurements and Main Results: Four weeks after transverse aorta constriction, Ephx2 (-/-) mice did not develop significant cardiac hypertrophy as that of wild-type mice, indicated by no changes in the ratio of heart weight/body weight and ventricular wall thickness after transverse aorta constriction. Cardiac fibroblast growth factor-2 increased in wild-type-transverse aorta constriction group but this did not change in Ephx2 (-/-)-transverse aorta constriction group, and the serum level of fibroblast growth factor-2 did not change in both groups. In vitro, cardiac fibroblasts were stimulated by angiotensin II to analyze the expression of fibroblast growth factor-2. The effect of increased fibroblast growth factor-2 from cardiac fibroblasts induced by angiotensin II was attenuated by soluble epoxide hydrolase deletion. ERK1/2, p38, and AKT kinase were involved in fibroblast growth factor-2 expression regulated by angiotensin II, and soluble epoxide hydrolase deletion lowered the phosphorylation of ERK1/2 not p38 or AKT to mediate fibroblast growth factor-2 expression. In addition, soluble epoxide hydrolase deletion did not attenuate cardiomyocytes hypertrophy induced by exogenous fibroblast growth factor-2. Conclusions: Our present data demonstrated that deletion of soluble epoxide hydrolase prevented cardiac hypertrophy not only directly to cardiomyocytes but also to cardiac fibroblasts by reducing expression of fibroblast growth factor-2.
KW - cardiac fibroblast
KW - cardiac hypertrophy
KW - fibroblast growth factor-2
KW - soluble epoxide hydrolase
UR - http://www.scopus.com/inward/record.url?scp=84899587395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899587395&partnerID=8YFLogxK
U2 - 10.1097/CCM.0000000000000226
DO - 10.1097/CCM.0000000000000226
M3 - Article
C2 - 24448199
AN - SCOPUS:84899587395
SN - 0090-3493
VL - 42
SP - e345-e354
JO - Critical Care Medicine
JF - Critical Care Medicine
IS - 5
ER -